文献速递产科母胎医学

「子痫前期与高血压目标治疗」研究:一项多中心前瞻性研究,评估基于母体血流动力学发现的高血压治疗的有效性

The "Preeclampsia and Hypertension Target Treatment" study: a multicenter prospective study to evaluate the effectiveness of the antihypertensive therapy based on maternal hemodynamic findings.
PubMed 文献 · Am J Obstet Gynecol MFM · 2024-04-03

该多中心前瞻性研究纳入152例新发妊娠期高血压疾病孕妇,入院时用超声心输出量监测仪评估血流动力学,临床医生不知情下按常规选择一线降压药。回顾性判断治疗与血流动力学是否匹配后比较发现,匹配组分娩前重度高血压发生率显著低于不匹配组(6.0% vs 19.4%,P=.02),48至72小时内血压达标率更高(70.7% vs 50.0%,P=.02)。

要点

  • 新发妊娠期高血压疾病孕妇中,多数(114例,75.0%)呈低动力型血流动力学。
  • 匹配组分娩前重度高血压发生率为6.0%,不匹配组为19.4%(P=.02)。
  • 匹配组48至72小时内血压达标率为70.7%,不匹配组为50.0%(P=.02)。

核心结论

  • 在新发妊娠期高血压疾病孕妇中,当一线降压药根据正确的母体血流动力学特征进行选择时,观察到重度高血压的发生率更低。

研究设计与样本

  • 这是一项前瞻性多中心研究,纳入新发妊娠期高血压疾病孕妇152例进行最终分析。
  • 入院后给予任何降压治疗前,通过超声心输出量监测仪无创评估母体心输出量、心率、体循环血管阻力和每搏输出量。
  • 处方降压药的临床医生对血流动力学评估结果不知情,根据个人偏好或当地方案选择一线药物:血管扩张剂(硝苯地平或α甲基多巴)或β受体阻滞剂(拉贝洛尔)。
  • 一线药物治疗后被回顾性判定为血流动力学匹配的情形包括:(1)低动力型(心输出量≤5 L/min和/或体循环血管阻力≥1300 dynes/second/cm2)者接受口服硝苯地平或α甲基多巴;(2)高动力型(心输出量正常或偏高>5 L/min和/或体循环血管阻力偏低<1300 dynes/second/cm2)者接受口服拉贝洛尔。
  • 主要结局是比较接受血流动力学匹配治疗与不匹配治疗的孕妇之间重度高血压的发生情况。

主要发现

  • 多数孕妇表现为低动力型(114例,75.0%),并接受了血流动力学匹配治疗(116例,76.3%)。
  • 分娩前重度高血压发生率在匹配治疗组为6.0%,在不匹配治疗组为19.4%,匹配组显著低于不匹配组(P=.02)。
  • 治疗开始后48至72小时内达到目标血压值的孕妇比例在匹配治疗组为70.7%,在不匹配治疗组为50.0%,匹配组高于不匹配组(P=.02)。

关键数值与推荐

  • 低动力型定义为心输出量≤5 L/min和/或体循环血管阻力≥1300 dynes/second/cm2。
  • 高动力型定义为心输出量正常或偏高>5 L/min和/或体循环血管阻力偏低<1300 dynes/second/cm2。
  • 血流动力学匹配治疗:低动力型者接受口服硝苯地平或α甲基多巴;高动力型者接受口服拉贝洛尔。
  • 主要结局为分娩前重度高血压的发生;次要观察包括治疗开始后48至72小时内血压达标情况。

临床怎么用

  • 作者结论认为,在新发妊娠期高血压疾病孕妇中,一线降压药根据正确的母体血流动力学特征进行选择时,观察到重度高血压发生率更低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite major advances in the pharmacologic treatment of hypertension in the nonpregnant population, treatments for hypertension in pregnancy have remained largely unchanged over the years. There is recent evidence that a more adequate control of maternal blood pressure is achieved when the first given antihypertensive drug is able to correct the underlying hemodynamic disorder of the mother besides normalizing the blood pressure values. OBJECTIVE: This study aimed to compare the blood pressure control in women receiving an appropriate or inappropriate antihypertensive therapy following the baseline hemodynamic findings. STUDY DESIGN: This was a prospective multicenter study that included a population of women with de novo diagnosis of hypertensive disorders of pregnancy. A noninvasive assessment of the following maternal parameters was performed on hospital admission via Ultrasound Cardiac Output Monitor before any antihypertensive therapy was given: cardiac output, heart rate, systemic vascular resistance, and stroke volume. The clinician who prescribed the antihypertensive therapy was blinded to the hemodynamic evaluation and used as first-line treatment a vasodilator (nifedipine or alpha methyldopa) or a beta-blocker (labetalol) based on his preferences or on the local protocols. The first-line pharmacologic treatment was retrospectively considered hemodynamically appropriate in either of the following circumstances: (1) women with a hypodynamic profile (defined as low cardiac output [≤5 L/min] and/or high systemic vascular resistance [≥1300 dynes/second/cm2]) who were administered oral nifedipine or alpha methyldopa and (2) women with a hyperdynamic profile (defined as normal or high cardiac output [>5 L/min] and/or low systemic vascular resistances [<1300 dynes/second/cm2]) who were administered oral labetalol. The primary outcome of the study was to compare the occurrence of severe hypertension between women treated with a hemodynamically appropriate therapy and women treated with an inappropriate therapy. RESULTS: A total of 152 women with hypertensive disorders of pregnancy were included in the final analysis. Most women displayed a hypodynamic profile (114 [75.0%]) and received a hemodynamically appropriate treatment (116 [76.3%]). The occurrence of severe hypertension before delivery was significantly lower in the group receiving an appropriate therapy than in the group receiving an inappropriately treated (6.0% vs 19.4%, respectively; P=.02). Moreover, the number of women who achieved target values of blood pressure within 48 to 72 hours from the treatment start was higher in the group who received an appropriate treatment than in the group who received an inappropriate treatment (70.7% vs 50.0%, respectively; P=.02). CONCLUSION: In pregnant individuals with de novo hypertensive disorders of pregnancy, a lower occurrence of severe hypertension was observed when the first-line antihypertensive agent was tailored to the correct maternal hemodynamic profile.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. di Pasquo E, Giannubilo SR, Valentini B, et al. The "Preeclampsia and Hypertension Target Treatment" study: a multicenter prospective study to evaluate the effectiveness of the antihypertensive therapy based on maternal hemodynamic findings. Am J Obstet Gynecol MFM. 2024. PMID: 38574856. doi:10.1016/j.ajogmf.2024.101368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。